加载中
NASDAQHealthcareBiotechnology
最新数据
US$8.59
+US$0.025 · +0.29%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
常规交易时段
US$8.59
+US$0.025 · +0.29%
盘中时间采用ET。市场数据可能有所延迟。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日内区间
当前US$8.59
52周区间
当前US$8.59
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
25
偏贵
情绪
49
多空交织
风险
46
风险偏高
动量
63
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日内区间
当前US$8.59
52周区间
当前US$8.59
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 5000万 USD | — | — |
| 销货成本 | — | 25.8万 USD | — | — | — |
| 毛利 | — | −25.8万 USD | 5000万 USD | — | — |
| 研究与开发 | 5152.2万 USD | 3816.4万 USD | 2760.3万 USD | 1689.4万 USD | 2236万 USD |
| 销售、一般及管理费用 | 1653.7万 USD | 1247.2万 USD | 632万 USD | 582.6万 USD | 628.7万 USD |
| 营业费用 | 6805.9万 USD | 5063.6万 USD | 6607.7万 USD | 2272万 USD | 2864.7万 USD |
| 利息收入 | 824.6万 USD | 890.5万 USD | 460.6万 USD | 76.1万 USD | 7.7万 USD |
| 利息支出 | — | — | 20.8万 USD | 38.8万 USD | 33.2万 USD |
| 折旧和摊销 | 32.3万 USD | 25.8万 USD | 19.5万 USD | 32.9万 USD | 32.5万 USD |
| 营业利润 | −6805.9万 USD | −5089.4万 USD | −1607.7万 USD | −2272万 USD | −2864.7万 USD |
| 净利润 | −5997.8万 USD | −4225.8万 USD | 2272万 USD | −2425.3万 USD | −2900.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$21.33
上涨空间 148.31%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1595.19万0.00%2.3万亿 USD0.03%US$381.09-0.13%
iShares Russell 2000 ETFIWM608.39万0.01%787.4亿 USD0.19%US$276.58-0.48%
Vanguard Extended Market ETFVXF498万0.01%954亿 USD0.05%US$232.07-0.62%
Vanguard Russell 2000 ETFVTWO251.11万0.01%180亿 USD0.06%US$111.69-0.52%
iShares Russell 2000 Value ETFIWN217万0.02%137.49亿 USD0.24%US$210.69-0.19%
iShares Biotechnology ETFIBB199.49万0.02%108.2亿 USD0.44%US$200.55-1.82%
State Street SPDR S&P Pharmaceuticals ETFXPH196.97万0.42%4.69亿 USD0.35%US$62.725-2.01%
Schwab U.S. Small-Cap ETFSCHA136.89万0.01%217.13亿 USD0.03%US$32.525-0.41%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
